229 related articles for article (PubMed ID: 23209034)
21. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
22. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
23. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
24. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
25. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
26. Current approaches to challenging scenarios in myeloproliferative neoplasms.
Zimran E; Hoffman R; Kremyanskaya M
Expert Rev Anticancer Ther; 2018 Jun; 18(6):567-578. PubMed ID: 29575945
[TBL] [Abstract][Full Text] [Related]
27. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
28. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
29. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
30. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
31. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
32. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
33. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
Willekens C; Laplane L; Dagher T; Benlabiod C; Papadopoulos N; Lacout C; Rameau P; Catelain C; Alfaro A; Edmond V; Signolle N; Marchand V; Droin N; Hoogenboezem R; Schneider RK; Penson A; Abdel-Wahab O; Giraudier S; Pasquier F; Marty C; Plo I; Villeval JL; Constantinescu SN; Porteu F; Vainchenker W; Solary E
Leukemia; 2023 Jun; 37(6):1287-1297. PubMed ID: 37100881
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
[TBL] [Abstract][Full Text] [Related]
35. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
Levine RL; Wernig G
Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
[TBL] [Abstract][Full Text] [Related]
36. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.
Gerds AT
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):407-414. PubMed ID: 31808852
[TBL] [Abstract][Full Text] [Related]
37. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
38. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
[TBL] [Abstract][Full Text] [Related]
39. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
40. Mutant calreticulin in myeloproliferative neoplasms.
How J; Hobbs GS; Mullally A
Blood; 2019 Dec; 134(25):2242-2248. PubMed ID: 31562135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]